School of Public Health and Community Medicine, Faculty of Medicine, The University of New South Wales, Sydney, Australia.
BMC Infect Dis. 2010 Apr 19;10:99. doi: 10.1186/1471-2334-10-99.
On the 30th September 2009, the pandemic (H1N1) 2009 influenza vaccine was made available to adults and children aged 10 years and over, in Australia. Acceptance of a novel vaccine is influenced by perceptions of risk including risk of infection, risk of death or severe illness and risk of serious vaccine side-effects. We surveyed a sample of residents from Sydney, Australia to ascertain their risk perception, attitudes towards the pandemic and willingness to accept the pandemic (H1N1) 2009 influenza vaccine.
We sampled residents using a cross-sectional intercept design during the WHO Phase 6. Members of the public were approached in shopping and pedestrian malls to undertake the survey during September and October 2009. The survey measured perceived risk, seriousness of disease, recent behavioural changes, likely acceptance of the pandemic (H1N1) 2009 vaccine and issues relating to uptake and perceived safety.
Of the 627 respondents, the majority felt that they had a "very low to low" (332/627, 52.9%) risk of acquiring H1N1. 24.5% (154/627) of respondents believed that the disease would "very seriously or extremely" affect their health. Nearly half (305/627, 48.6%) reported that in response to the "swine flu" outbreak they had undertaken one or more of the investigated behavioural changes. Overall, the self-reported likelihood of accepting vaccination against novel H1N1 was 54.7% (343/627).
While, most participants did not believe they were at high risk of acquiring pandemic H1N1 2009, over half of the sample indicated that they would accept the vaccine. Participants who were vaccinated against the seasonal influenza were more likely to receive the H1N1 vaccine. Concerns about safety, the possibility of side effects and the vaccine development process need to be addressed.
2009 年 9 月 30 日,大流行性(H1N1)2009 流感疫苗开始提供给 10 岁及以上的成人和儿童使用。对新型疫苗的接受程度受到包括感染风险、死亡或重病风险以及严重疫苗副作用风险等因素的认知的影响。我们对澳大利亚悉尼的居民进行了抽样调查,以了解他们对大流行的风险认知、态度以及对大流行性(H1N1)2009 流感疫苗的接受意愿。
我们在世界卫生组织第 6 阶段期间采用横断面拦截设计对居民进行抽样。在 2009 年 9 月和 10 月期间,在购物区和步行街向公众成员提出调查要求。该调查衡量了感知风险、疾病严重性、最近的行为变化、对大流行性(H1N1)2009 疫苗的可能接受程度以及与接种和感知安全性有关的问题。
在 627 名受访者中,大多数人认为他们(332/627,52.9%)感染 H1N1 的风险“非常低到低”。24.5%(154/627)的受访者认为该疾病将“非常严重或极其”影响他们的健康。近一半(305/627,48.6%)的受访者报告说,针对“猪流感”爆发,他们已经采取了一项或多项调查中的行为变化。总体而言,自我报告对接受新型 H1N1 疫苗接种的可能性为 54.7%(343/627)。
虽然大多数参与者并不认为自己感染大流行性(H1N1)2009 的风险很高,但样本的一半以上表示他们将接受疫苗。接种季节性流感疫苗的参与者更有可能接种 H1N1 疫苗。需要解决对安全性、副作用可能性和疫苗开发过程的担忧。